Amnion-derived cells, methods of making and uses thereof

• US 8,877,181 B2
• Filed: 10/03/2012
• Issued: 11/04/2014
• Est. Priority Date: 03/31/2005
• Status: Active Grant

• Current Assignee: Stemnion, Inc.
• Original Assignee: Stemnion, Inc.
• Inventors: Emig, Charlotte, Marshall, Vivienne S, Banas, Richard A
• Primary Examiner(s): Driscoll, Lora E Barnhart
• Application Number:
  US13/644,026
• Publication Number:
  US 20130071363A1
• Time in Patent Office: 762 Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2800/10 General cosmetic use
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 8/982 Reproductive organs; Embryos, Eggs
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2502/02 embryonic cells
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0629 Keratinocytes; Whole skin

Abstract

The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.

Claims

1. A composition comprising:

a) a first component consisting of a substantially purified population of cultured amnion-derived cells, wherein the substantially purified population of cultured amnion-derived cells are made by a method comprising the steps of

i) obtaining a placenta and isolating an amnion from the placenta,

ii) enzymatically releasing amnion-derived epithelial cells from the amnion,

iii) collecting the released amnion-derived epithelial cells, and

iv) culturing the collected amnion-derived epithelial cells of step (iii) in basal culture medium that is supplemented with human serum albumin and, optionally, further supplemented with recombinant human protein factors capable of stimulating proliferation of the cultured amnion-derived epithelial cells; and

b) a second component consisting of a matrix selected from the group consisting of a polyglycolic acid, a polyanhydride, a polyorthoester, and a polylactic acid.

2. The composition of claim 1 wherein the matrix is selected from the group consisting of a gel, an extracellular matrix, and a 3-dimensional scaffold.

3. The composition of claim 2 wherein the gel is selected from the group consisting of an ointment, a salve, and a cream, and a gel matrix.